Highlight selection of radiochemistry and radiopharmacy developments by editorial board

Jun Toyohara; Mohammed Al-Qahtani; Ya-Yao Huang; Emiliano Cazzola; Sergio Todde; Shozo Furumoto; Renata Mikolajczak; Clemens Decristoforo; Nic Gillings; Min Yang; Raymond Reilly; Adriano Duatti; Antonia Denkova; Ralf Schirrmacher; Giuseppe Carlucci; Yann Seimbille; Zhaofei Liu; Beverley Ellis; Bart T Cornelissen; Klaus Kopka; Emerson Bernardes

doi:10.1186/s41181-022-00177-w

Highlight selection of radiochemistry and radiopharmacy developments by editorial board

EJNMMI Radiopharm Chem. 2022 Oct 1;7(1):25. doi: 10.1186/s41181-022-00177-w.

Authors

Jun Toyohara¹, Mohammed Al-Qahtani², Ya-Yao Huang³, Emiliano Cazzola^{4

5}, Sergio Todde⁶, Shozo Furumoto⁷, Renata Mikolajczak^{8

9}, Clemens Decristoforo¹⁰, Nic Gillings¹¹, Min Yang¹², Raymond Reilly¹³, Adriano Duatti^{14

15}, Antonia Denkova¹⁶, Ralf Schirrmacher¹⁷, Giuseppe Carlucci¹⁸, Yann Seimbille¹⁹, Zhaofei Liu²⁰, Beverley Ellis²¹, Bart T Cornelissen²², Klaus Kopka²³, Emerson Bernardes^{24

25}

Affiliations

¹ PET Radiopharmaceutical Sciences, Research Team for Neuroimaging, Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan.
² Cyclotron and Radiopharmaceuticals Department, King Faisal Specialist Hospital and Research Center (KFSHRC), Riyadh, Saudi Arabia.
³ Molecular Imaging Center, National Taiwan University, Taipei, Taiwan.
⁴ Scientific Institute for Research, Hospitalization and Healthcare (IRCCS), Sacro Cuore-Don Calabria Hospital, Negrar (Vr), Italy.
⁵ Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Ospedale Sacro Cuore-Don Calabria, Negrar (Vr), Italia.
⁶ University of Milano-Bicocca, Tecnomed Foundation, Monza, Italy.
⁷ Cyclotron and Radioisotope Center (CYRIC), Tohoku University, Sendai, Japan.
⁸ Radioisotope Centre POLATOM, National Centre for Nuclear Research (NCBJ), Otwock, Poland.
⁹ Ośrodek Radioizotopów POLATOM, NARODOWE CENTRUM BADAŃ JĄDROWYCH (NCBJ), Otwock, Poland.
¹⁰ Department of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, Austria.
¹¹ Department of Clinical Physiology and Nuclear Medicine, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark.
¹² NHC Key Laboratory of Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi, Jiangsu, China.
¹³ Department of Pharmaceutical Sciences, Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON, Canada.
¹⁴ Department of Chemical, Pharmaceutical and Agricultural Sciences, University of Ferrara, Ferrara, Italy.
¹⁵ Dipartimento di Scienze Chimiche, Farmaceutiche e Agrarie Università di Ferrara, Ferrara, Italia.
¹⁶ Department of Radiation Science and Technology, Delft University of Technology, Delft, The Netherlands.
¹⁷ Department of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada.
¹⁸ Department of Molecular and Medical Pharmacology, University of California, Los Angeles (UCLA), Los Angeles, CA, USA.
¹⁹ Department of Radiology and Nuclear Medicine, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.
²⁰ Medical Isotopes Research Center, Department of Radiation Medicine, School of Basic Medical Sciences, Peking University Health Science Centre, Beijing, China.
²¹ Manchester University NHS Foundation Trust, Manchester, UK.
²² Department of Nuclear Medicine and Molecular Imaging, Groningen (UMCG), University Medical Center, University of Groningen, Groningen, The Netherlands.
²³ Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Institute of Radiopharmaceutical Cancer Research, Dresden, Germany. k.kopka@hzdr.de.
²⁴ Energy and Nuclear Research Institute (IPEN-CNEN/SP), Cidade Universitária, São Paulo, Brazil.
²⁵ Instituto de Pesquisas Energéticas e Nucleares (IPEN-CNEN/SP), Cidade Universitária, São Paulo, Brasil.

Abstract

Background: The Editorial Board of EJNMMI Radiopharmacy and Chemistry releases a biannual highlight commentary to update the readership on trends in the field of radiopharmaceutical development.

Main body: This commentary of highlights has resulted in 21 different topics selected by each coauthoring Editorial Board member addressing a variety of aspects ranging from novel radiochemistry to first in man application of novel radiopharmaceuticals.

Conclusion: Trends in radiochemistry and radiopharmacy are highlighted demonstrating the progress in the research field in various topics including new PET-labelling methods, FAPI-tracers and imaging, and radionuclide therapy being the scope of EJNMMI Radiopharmacy and Chemistry.

Keywords: Highlight Articles; Nuclear Medicine; Radiochemistry; Radiopharmaceutical Sciences; Radiopharmacy; Trends in Radiopharmaceutical Sciences.

Publication types

Review

Abstract

Publication types

Grants and funding